Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bayer HealthCare AG
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Study to evaluate the safety and pharmacokinetics of ciprofloxacin following inhalation of ciprofloxacin dry powder for inhalation administered to pediatric patients with cystic fibrosis aged 12-17 years
Primary objective of the study is to investigate the safety and tolerability of inhaled ciprofloxacin given as single inhalation dose to pediatric CF patients.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A prospective, randomized, double dummy, double blind, multinational, multicenter trial comparing the safety and efficacy of sequential (intravenous/oral) moxifloxacin 400 mg once daily to intravenous piperacillin/tazobactam 4.0/0.5 g every 8 hours followed by oral amoxicillin/clavulanic acid tablets 875/125 mg every 12 hours for the treatment of subjects with complicated skin and skin structure infections (RELIEF Study)
The objective of this study is to compare the efficacy and safety of two sequential (IV/PO) treatment regimens for the treatment of adult subjects with cSSSIs: • Moxifloxacin, 400 mg IV every 24 hours...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG, Bayer Vital GmbH, D-51368 Leverkusen
MAJ Il y a 5 ans
Estudio de extensión a largo plazo, multicéntrico y multinacional, para evaluar la seguridad y tolerabilidad de BAY 63 2521 (1 mg, 1,5 mg, 2 mg o 2,5 mg tid) administrado por vía oral, en pacientes con Hipertensión Pulmonar Tromboembólica Crónica (HPTEC) Estudio CHEST-2
Long-term safety and tolerability of BAY 63-2521 in patients with inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) or recurrent or persisting pulmonary hypertension after surgical trea...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A Phase 2/ 3 trial to evaluate the efficacy and safety of BAY86-6150 Studio di Fase II/III per valutare la sicurezza e l’efficacia di BAY 86-6150
Part A: - To identify the recommended dose by conducting a risk-benefit assessment of four different dose levels of BAY 86-6150 based on safety and dose response assessments in acutely bleeding subje...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
RECORD 1 Study: REgulation of Coaculation in ORthopedic Surgery to prevent DVT and PE, controlled, double-blind, randomized study of BAY 59-7939 in the extended prevention of VTE in patients undergoing elective total hip replacement
The objective of this trial is to assess the efficacy and safety of BAY 59-7939 10 mg once daily dosing in extended prevention of VTE in men and women aged 18 years or above undergoing elective total ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia A
The primary objective is to evaluate the effect of a once-a-week prophylaxis regimen with BAY 79-4980 on the protection from total bleeds compared to a three times-per-week prophylaxis regimen with rF...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
RECORD 2 Study: REgulation of Coagulation in ORthopedic Surgery to prevent DVT and PE, controlled, Double-Blind, Randomized Study of BAY59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
The objective of this trial is to compare the efficacy and safety of VTE prophylaxis with BAY 59-7939 10 mg once daily administered for 5 weeks to enoxaparin 40 mg once daily (qd) administered for 10-...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A study to test the safety and effectiveness of a tablet containing both Nifedipine and Candesartan Cilexetil in adult patients with moderate to severe high blood pressure
The primary objective is to evaluate the long-term safety and tolerability of FDC of nifedipine GITS / candesartan cilexetil (primarily the highest dose) once daily in subjects with moderate to sever...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Multi-center, double-blind, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) compared to a monophasic contraceptive containing ethinylestradiol and levonorgestrel (Microgynon) over 6 treatment cycles on alleviating complaints of reduced libido in women with acquired female sexual dysfunction (FSD) associated with oral contraceptive use
The primary objective of this study is to show non-inferiority of SH T00658ID to Microgynon on libido in women with acquired female sexual dysfunction (FSD) associated with OC-use.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of Low Dose BAY 58-2667 (25 μg/h, 10 μg/h) Given Intravenously to Subjects with Acute Decompensated Chronic Congestive Heart Failure (ADHF)
The primary objective of this study is to investigate the safety and efficacy of a fixed dose (10 µg/h or 25 µg/h) over at least 24 hours and up to 48 hours of intravenous BAY 58-2667 in subjects with...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
5
6
7
8
9
10
11
12
13
14
Suivant